<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">IJPharm</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0253-7613</issn>
      <issn pub-type="epub">1998-3751</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25298593</article-id>
      <article-id pub-id-type="pmc">4175900</article-id>
      <article-id pub-id-type="publisher-id">IJPharm-46-560</article-id>
      <article-id pub-id-type="doi">10.4103/0253-7613.140599</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Watch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Levetiracetam induced acute reversible psychosis in a patient with uncontrolled seizures</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>Nithin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Swaroop</surname>
            <given-names>H. S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chakraborty</surname>
            <given-names>Ananya</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chandran</surname>
            <given-names>Suhas</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Neurology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India</aff>
      <aff id="aff2"><label>1</label>Department of Pharmacology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Dr. Ananya Chakraborty E-mail: <email xlink:href="dr_ananya@yahoo.com">dr_ananya@yahoo.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <volume>46</volume>
      <issue>5</issue>
      <fpage>560</fpage>
      <lpage>561</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>22</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Pharmacology</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Levetiracetam (LEV) is a relatively newer antiepileptic drug with novel mechanism of action. It was introduced to the market in the year 2000. Pre-marketing clinical trials of the drug reported good tolerability with a wide safety margin. On post-marketing updates, there are few reports of psychosis after treatment with the drug. Here, we report a case of 52-year-old epileptic man who developed acute, reversible psychosis within 3 days of initiation of treatment. The drug was prescribed at a dose of 500 mg per day. After 3 days of treatment, the patient developed visual hallucinations, mood swings, withdrawal and suspicious behavior. Delirium was ruled out as there was no fluctuation in his sensorium or focal neurological deficits. His lab investigations for electrolytes, renal function test, thyroid, liver function and other related tests levels were within normal limits. A diagnosis of LEV induced psychosis was reached based on clinical judgment and causality assessment.</p>
      </abstract>
      <kwd-group>
        <title>KEY WORDS</title>
        <kwd>Adverse drug reaction</kwd>
        <kwd>antiepileptic drugs</kwd>
        <kwd>anti-seizure drug</kwd>
        <kwd>levetiracetam</kwd>
        <kwd>psychosis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>Introduction</title>
      <p>Levetiracetam (LEV) is a novel second generation anti-epileptic drug. It is chemically unrelated to other antiepileptic drugs and is the &#x3B1;-ethyl analogue of the nootropic agent piracetam.[<xref rid="ref1" ref-type="bibr">1</xref>] It is postulated to act by binding to synaptic vesicle protein 2A (SV2A) and thereby modulation of one or more of its actions, ultimately affecting neural excitability.[<xref rid="ref2" ref-type="bibr">2</xref>] It has been found to be well-tolerated and has a favorable pharmacokinetic profile that includes minimal protein binding, lack of hepatic metabolism and twice a day dosing. LEV has a wide safety margin without any requirement for serum drug monitoring.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] The reported central nervous system adverse drug reactions (ADR) of LEV are somnolence, asthenia, coordination difficulties, and behavioral abnormalities. Psychosis has been reported infrequently with LEV with a reported frequency of less than 1%.[<xref rid="ref5" ref-type="bibr">5</xref>] Here, we report a case of acute, reversible psychosis in a 52-year-old epileptic man on LEV therapy.</p>
    </sec>
    <sec id="sec1-2">
      <title>Case Report</title>
      <p>A 52-year-old male epileptic patient was brought to our tertiary care hospital with uncontrolled seizure. He had history of focal epilepsy since 5 years and was on antiepileptic medication. He was on carbamazepine, with a total dose of 1000 mg per day, since 1 year. He was apparently doing alright for some time and his quality of life had improved on carbamazepine. However, the seizures recurred once in every 2-3 weeks for the last 3 months because of which he was admitted in neurology department for further management and drug optimization.</p>
      <p>His general physical examination was normal. There was no history of prior behavioral problems or cognitive deficits. There was no family history of psychotic disorder. His blood investigations for electrolytes, renal function test, thyroid, liver function and other related tests were within normal limits. His computed tomography (CT) scan of brain showed left frontal calcified lesion suggestive of cysticercosis. His CT brain with contrast showed no further new or active lesions. His EEG was normal. His serum carbamazepine level was 10 &#x3BC;g/ml.</p>
      <p>In view of his poor seizure control and serum carbamazepine level reaching the upper limits of normal, he was added on LEV with an initial dose of 250 mg twice a day and was planned to increase the dose gradually over 2-4 weeks to reach a dose up to a total 1000 mg per day. However, by day 3 the patient developed severe behavioral abnormality characterized by agitation, emotional liability, hostility and depersonalization. He was evaluated by the psychiatrist and was diagnosed as acute psychosis. His mental state examination was normal except for abnormal mood and thoughts. Psychiatric assessment revealed features of depression, mood and thought abnormality, suspicious and withdrawal state with visual hallucination suggestive of psychosis. Delirium was ruled out as there was no fluctuation in sensorium, focal deficits and meningeal signs. As mentioned earlier, the lab investigations were done to rule out metabolic causes of this clinical presentation.</p>
      <p>Considering the possibility of drug induced psychosis, LEV was withheld. Within 48 hours, the patient recovered from psychosis, without any treatment. Later, he was added on valproic acid for the management of seizures. The adverse drug reaction causality assessment was done using the Naranjo scale.[<xref rid="ref6" ref-type="bibr">6</xref>] The causal analysis showed a probable association (score 5) of the reaction with LEV.</p>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>Discussion</title>
      <p>Many patients with epilepsy suffer also from coexisting psychological problems. Neurobehavioral adverse effects are also very common with recently introduced antiepileptic drugs.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>] LEV is a newer antiepileptic drug that has shown promise in a number of long term, open label, follow up clinical studies. The drug is reported to have significant safety margin with ADR like dizziness, fatigue, headache, upper respiratory tract infection, and somnolence. Although it has a favorable profile, behavioral ADRs are reported in up to 13.3% of the drug users.[<xref rid="ref5" ref-type="bibr">5</xref>] Of these, severe symptoms such as depression, agitation, hostility and psychotic behavior are experienced by 0.7% of the patients.[<xref rid="ref9" ref-type="bibr">9</xref>] LEV psychosis is reported to be common in patients with preexisting psychotic disorder, also in patients on add-on therapy, and rapid titration when there is an underlying neurological disease.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref10" ref-type="bibr">10</xref>] LEV Psychosis is also reported to be common in children with prior cognitive defects who receive prescription of the drug.[<xref rid="ref9" ref-type="bibr">9</xref>]</p>
      <p>Our patient did not provide any history of preexisting psychotic disorder or family history of preexisting psychotic disorder. The psychosis episode was also evident at clinically permissible dose range and at the onset of therapy. Previous case reports demonstrated the problem with either increase in the drug dose[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref11" ref-type="bibr">11</xref>] or after 10 days to one month of initiation of therapy.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref12" ref-type="bibr">12</xref>] However, like the previous reports, our patient also recovered after prompt withdrawal of the drug.</p>
      <p>Psychiatric ADRs are common with antiepileptic drugs. The mechanism for this psychosis remains unclear. At present, there is no evidence to suggest that LEV produces psychosis at significantly higher rates than other antiepileptic drugs.[<xref rid="ref13" ref-type="bibr">13</xref>] However, detailed clinical history and close monitoring with regard to psychiatric adverse effects should be advocated when starting treatment with LEV. It is especially important in patients with risk factors for psychiatric adverse effects. Also, further studies to assess the behavioral profile of LEV in large group of patients should be initiated.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> No</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haria</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Balfour</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Levetiracetam</article-title>
          <source>CNS Drugs</source>
          <year>1997</year>
          <volume>7</volume>
          <fpage>159</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">23338133</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Lambeng</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nocka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hammes</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bajjalieh</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Matagne</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>9861</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">15210974</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogawski</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Brivaracetam: A rational drug discovery success story</article-title>
          <source>Br J Pharmacol</source>
          <year>2008</year>
          <volume>154</volume>
          <fpage>1555</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">18552880</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abou-Khalil</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Levetiracetam in the treatment of epilepsy</article-title>
          <source>Neuropsychiatr Dis Treat</source>
          <year>2008</year>
          <volume>4</volume>
          <fpage>507</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">18830435</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>DuttSharma</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Probable psychosis associated with levetiracetam: A case report</article-title>
          <source>J Neuropsych Clin North</source>
          <year>2011</year>
          <volume>23</volume>
          <fpage>E19</fpage>
          <lpage>20</lpage>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="webpage">
          <article-title>Adverse drug reaction probability scale (Naranjo)</article-title>
          <date-in-citation>Last accessed on 2013 Dec18</date-in-citation>
          <comment>Available from: 
<uri xlink:type="simple" xlink:href="http://livertox.nih.gov/Narajoh.html">http://livertox.nih.gov/Narajoh.html</uri></comment>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bath</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Scharfman</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
          <article-title>Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research</article-title>
          <source>Epilepsy Behav</source>
          <year>2013</year>
          <volume>26</volume>
          <fpage>427</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="pmid">23305780</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sedighi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Seifaddini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Iranmanesh</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Alhasani</surname>
              <given-names>YM</given-names>
            </name>
          </person-group>
          <article-title>Antiepileptic drugs and mental health status of patients with epilepsy</article-title>
          <source>Iran J Pharmacol Ther</source>
          <year>2013</year>
          <volume>12</volume>
          <fpage>66</fpage>
          <lpage>70</lpage>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dannaram</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borra</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pulluri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jindal</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Levetiracetam induced acute psychotic episode</article-title>
          <source>Innov Clin Neurosci</source>
          <year>2012</year>
          <volume>9</volume>
          <fpage>10</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">23198271</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delanty</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tonner</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Open-label, noncomparative, multicenter, long-term follow-up study</article-title>
          <source>Epilepsia</source>
          <year>2012</year>
          <volume>53</volume>
          <fpage>111</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">22050371</pub-id>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kossoff</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Bergey</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Vining</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>Levetiracetam psychosis in children with epilepsy</article-title>
          <source>Epilepsia</source>
          <year>2001</year>
          <volume>42</volume>
          <fpage>1611</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">11879376</pub-id>
        </element-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <name>
              <surname>Rajdeep</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Harish</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Nonepileptic hallucinations with the use of levetiracetam: A case report</article-title>
          <date-in-citation>Last accessed on 2013 Dec 20</date-in-citation>
          <comment>Available from: 
<uri xlink:type="simple" xlink:href="http://www.mjpsychiatry.org/index.php/mjp/article/viewFile/80/77">http://www.mjpsychiatry.org/index.php/mjp/article/viewFile/80/77</uri></comment>
        </element-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Youroukos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lazopoulou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Michelakou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Karagianni</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Acute psychosis associated with levetiracetam</article-title>
          <source>Epileptic Disord</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>117</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">12875956</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
